A unique platform combining several technologies accelerated by AI for the discovery of new drug candidates impacting longevity
Biophytis provides an update on the modification of the terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first time on February 26, 2026, and amended a second time on May 22, 2026. These changes are part of Biophytis’…
Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC, widely recognized as one of the world’s leading conferences dedicated to artificial intelligence and accelerated computing. The event brought together…
Biophytis SA announces that it participated in the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR), held from March 10 to 12, 2026 in Washington, DC (United States).
Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research Next-generation drug candidates against sarcopenia Next generation drug candidates for dry age-related macular…
Biophytis SA today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription rights of the Company’s existing shareholders in favor of several institutional investors, for a total gross amount of €2,015,000 (the…
Biophytis SA announces several amendments to the bond financing announced on August 5, 2025, in joint agreement with Hexagon Capital Fund.
